Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Revenue of Ocugen, Inc. (OCGN)
Revenue in 2023 (TTM): $6.04 M
According to Ocugen, Inc.'s latest financial reports the company's current revenue (TTM) is $6.04 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ocugen, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $6.04 M | $5.33 M | $-64,827,000 | $-63,078,000 | $-63,078,000 |
| 2022 | $2.49 M | $1.42 M | $-88,591,000 | $-81,351,000 | $-77,834,000 |
| 2021 | $ | $-589,000 | $-58,028,000 | $-58,417,000 | $-58,365,000 |
| 2020 | $42.62 K | $36.27 K | $-20,998,882 | $-21,821,953 | $-22,623,468 |
| 2019 | $ | $-60,608 | $-18,414,183 | $-20,242,630 | $-21,225,593 |
| 2018 | $ | $-49,623 | $-14,419,413 | $-8,643,000 | $-8,643,000 |
| 2017 | $ | $-1,534,000 | $-24,880,000 | $-26,414,000 | $-26,414,000 |
| 2016 | $ | $-1,673,000 | $-11,375,000 | $-16,208,000 | $-16,208,000 |
| 2015 | $ | $-1,614,000 | $-30,277,000 | $-32,024,000 | $-32,024,000 |
| 2014 | $ | $ | $-21,915,999 | $-22,793,000 | $-22,793,000 |
| 2013 | $8 K | $8 K | $-16,219,000 | $-25,712,000 | $-25,712,000 |
| 2012 | $26 K | $26 K | $-14,330,000 | $-16,935,000 | $-16,935,000 |